Cidara Therapeutics EPS - Earnings per Share 2014-2022 | CDTX

Cidara Therapeutics eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Cidara Therapeutics Annual EPS
2021 $-0.81
2020 $-1.80
2019 $-1.37
2018 $-2.68
2017 $-3.18
2016 $-3.32
2015 $-3.25
2014 $-14.51
2013 $-4.15
Cidara Therapeutics Quarterly EPS
2022-03-31 $-0.27
2021-12-31 $-0.23
2021-09-30 $-0.37
2021-06-30 $0.18
2021-03-31 $-0.39
2020-12-31 $-0.48
2020-09-30 $-0.41
2020-06-30 $-0.45
2020-03-31 $-0.46
2019-12-31 $-0.40
2019-09-30 $0.08
2019-06-30 $-0.47
2019-03-31 $-0.58
2018-12-31 $-0.26
2018-09-30 $-0.49
2018-06-30 $-1.13
2018-03-31 $-0.80
2017-12-31 $-0.66
2017-09-30 $-0.73
2017-06-30 $-0.99
2017-03-31 $-0.80
2016-12-31 $-0.88
2016-09-30 $-0.88
2016-06-30 $-0.85
2016-03-31 $-0.71
2015-12-31 $3.93
2015-09-30 $-0.67
2015-06-30 $-0.59
2015-03-31 $-5.92
2014-12-31 $-4.68
2014-09-30 $-2.98
2014-06-30 $-5.04
2014-03-31 $-1.81
2013-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.031B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00